24 results
8-K
EX-99.1
KDNY
Chinook Therapeutics Inc
28 Jul 23
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
8:15am
-APRIL monoclonal antibody.
“Initiation of the phase 3 BEYOND study is an important step towards our goal of providing an innovative treatment option
DEFM14A
KDNY
Chinook Therapeutics Inc
10 Jul 23
Proxy related to merger
4:01pm
is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative … .
The Novartis Group is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative
PREM14A
KDNY
Chinook Therapeutics Inc
27 Jun 23
Preliminary proxy related to merger
4:02pm
in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. Buyer … is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals
DFAN14A
KDNY
Chinook Therapeutics Inc
12 Jun 23
Additional proxy materials by non-management
9:41am
https://twitter.com/novartisnews
MEDIA & INVESTOR RELEASE
Novartis bolsters innovative medicines strategy and renal pipeline with agreement … to customary closing conditions, is fully in line with Novartis strategy to focus on innovative medicines and will significantly expand its renal
PRE 14A
312fqho
17 Apr 23
Preliminary proxy
4:51pm
8-K
EX-99.1
k0mkxofo5yl3hbqnkhxx
30 Nov 21
Chinook Therapeutics Announces Formation of SanReno Therapeutics, a Joint Venture to Develop Kidney Disease Therapies in China
4:04pm
8-K
EX-99.1
wfoufhnyd9
18 Apr 19
Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors
4:10pm
8-K
EX-99.1
wc3xei2t4ogyunrmlpab
21 Nov 16
Other Events
12:00am